Form 4: Protara Therapeutics Executive Sells Shares

Chief R&D Officer Jacqueline Zummo sold 22,598 shares of Protara Therapeutics common stock via a 10b5-1 trading plan.

Summary

• Jacqueline Zummo, Chief R&D Officer of Protara Therapeutics, sold 22,598 shares of common stock.
• The transaction occurred on April 1, 2026, at a weighted average price of $5.26 per share.
• The sale was executed automatically under a Rule 10b5-1 trading plan established on December 31, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 95,961 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and executed through a standard 10b5-1 trading arrangement.

Positives

• The sale was conducted through a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the equity stake held by a key member of the R&D leadership team.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's near-term valuation.

Future Outlook

No forward-looking guidance regarding company operations or financial performance was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector and typically does not reflect a change in fundamental company strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected as the sale was conducted via a pre-arranged plan.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Protara Therapeutics, TARA, Insider Trading, Form 4, Biotech, Equity Sale